Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

计划入组 232 人 · 首次发布于 2026 年 7 月 6 日

Safety and Efficacy of YB-1113 in Treatment of POI

计划入组 6 人 · 首次发布于 2022 年 8 月 10 日

HP011-101, HP828-101, and Standard Care for Pressure Ulcers

首次发布于 2011 年 1 月 10 日

YB-001

YB-200

YB-800BS1

浙江章光101有限公司

EUN JUNG KIM

United States

北京章光101药业有限公司

GenSci Partners with RTW Investments in $1.365 Billion Deal for First-in-Class Thyroid Autoimmune Disease Therapy

VYNE Therapeutics and Yarrow Bioscience Merger Nears Completion: Cash Dividend Distributed, Reverse Stock Split Set, and YB-101 Poised to Advance Autoimmune Thyroid Disease Pipeline

Endeavor BioMedicines' ENV-101 Shows Promise in Reversing Idiopathic Pulmonary Fibrosis in Phase II Trials